Sorrento Therapeutics Inc. (SRNE): Price and Financial Metrics


Sorrento Therapeutics Inc. (SRNE): $9.07

-0.37 (-3.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 485

in industry

SRNE Stock Summary

  • With a price/sales ratio of 66.18, Sorrento Therapeutics Inc has a higher such ratio than 95.17% of stocks in our set.
  • With a year-over-year growth in debt of -41.75%, Sorrento Therapeutics Inc's debt growth rate surpasses just 7.84% of about US stocks.
  • As for revenue growth, note that SRNE's revenue has grown 27.21% over the past 12 months; that beats the revenue growth of 82.45% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sorrento Therapeutics Inc are MRCY, VUZI, JG, NSTG, and ACAD.
  • SRNE's SEC filings can be seen here. And to visit Sorrento Therapeutics Inc's official web site, go to www.sorrentotherapeutics.com.

SRNE Stock Price Chart Interactive Chart >

Price chart for SRNE

SRNE Price/Volume Stats

Current price $9.07 52-week high $19.39
Prev. close $9.44 52-week low $1.55
Day low $8.93 Volume 13,139,256
Day high $9.80 Avg. volume 20,437,359
50-day MA $10.53 Dividend yield N/A
200-day MA $8.58 Market Cap 2.55B

Sorrento Therapeutics Inc. (SRNE) Company Bio


Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.


SRNE Latest News Stream


Event/Time News Detail
Loading, please wait...

SRNE Latest Social Stream


Loading social stream, please wait...

View Full SRNE Social Stream

Latest SRNE News From Around the Web

Below are the latest news stories about Sorrento Therapeutics Inc that investors may wish to consider to help them evaluate SRNE as an investment opportunity.

Sorrento gets FDA go ahead for STI-6643 trial in solid tumor

The FDA has cleared Sorrento Therapeutics (SRNE) to initiate clinical trail of internally developed anti-CD47 monoclonal antibody, STI-6643.The initial clinical trial will be a basket trial entitled “A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Patients with Selected Relapsed or Refractory...

Seeking Alpha | March 2, 2021

Sorrento wins FDA go-ahead for early-stage STI-2099 COVID-19 trial

Sorrento Therapeutics (SRNE) has received clearance from the FDA for its Investigational New Drug application ((IND)) for its Phase 1 study of the safety and pharmacokinetics of intranasal ((IN)) STI-2099 ((COVIDROPS)) in both healthy volunteers and patients with mild COVID-19.Initial trials are expected to be followed by a Phase 2 trial...

Seeking Alpha | March 2, 2021

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients

FDA granted IND clearance today for the commencement of a Phase 1 safety and pharmacokinetic study for STI-2099 (COVIDROPS™) in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of STI-2020 (COVI-AMG™).Initial trials are expected to be followed by a Phase 2 trial in both mild and moderate COVID-19 patients, either as a stand-alone nasal application or as a combination nasal and intravenous administration.This is the first FDA clearance of a clinical trial of intranasal administration of a neutralizing antibody against the SARS-CoV-2 virus. SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has received clearance from the FDA for its Investigational N...

Yahoo | March 2, 2021

Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies

Internally developed fully human anti-CD47 antibody (STI-6643) cleared for basket trial;No complicated titration or priming dose of the antibody is required to reduce toxicity;This study will be conducted at the Moffitt Cancer Center in Tampa, FL with Dr. David A. Sallman as the coordinating lead investigator; andA second anti-CD47 antibody (IMC-002) discovered from Sorrento’s G-MAB™ library was previously cleared by the FDA for clinical trial, and is currently in human testing by ImmuneOncia Therapeutics, LLC, a joint venture between Sorrento (35% ownership) and Yuhan Corporation. SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the FDA has cleared Sorrento’s internally developed anti-CD47 monoclonal antibody, STI...

Yahoo | March 2, 2021

Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome

SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered into an exclusive licensing term sheet with Aardvark Therapeutics (“Aardvark”) to acquire Aardvark’s proprietary formulation, Delayed Burst Release Low Dose Naltrexone (DBR-LDN), or ARD-301, for the treatment of chronic pain, fibromyalgia, and chronic post-COVID syndrome (“long haul COVID” or “long COVID”) in multiple Phase 2 programs planned to be initiated this year. Following execution of the definitive agreement between the parties, Scilex plans to work with Aardvark to initiate a new Phase 2 trial this year for fibromyalgia, which Scilex believes will be an important milestone for treatin...

Yahoo | March 1, 2021

Read More 'SRNE' Stories Here

SRNE Price Returns

1-mo -38.00%
3-mo 13.80%
6-mo 38.05%
1-year 331.90%
3-year 25.97%
5-year 47.48%
YTD 32.89%
2020 101.92%
2019 40.83%
2018 -36.84%
2017 -22.45%
2016 -43.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0234 seconds.